Gonadotropin Releasing Hormone Agonists May Minimize Cyclophosphamide Associated Gonadotoxicity in SLE and Autoimmune Diseases

Zeev Blumenfeld; Or Mischari; Naomi Schultz; Nina Boulman; Alexandra Balbir‐Gurman

doi:10.1016/j.semarthrit.2011.05.008

Gonadotropin Releasing Hormone Agonists May Minimize Cyclophosphamide Associated Gonadotoxicity in SLE and Autoimmune Diseases

Zeev Blumenfeld, Or Mischari, Naomi Schultz, Nina Boulman, Alexandra Balbir‐Gurman

In: Seminars in Arthritis and Rheumatism · 2011 · vol. 41(3) , pp. 346–352 · doi:10.1016/j.semarthrit.2011.05.008 · PMID:21868068 · W2158287250

article OA: closed CC0 ⤵ 4 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study investigated whether gonadotropin-releasing hormone agonists could protect against cyclophosphamide-induced damage to reproductive organs in patients with systemic lupus erythematosus and other autoimmune conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (4)

References (47)

Prevention of severe menorrhagia in oncology patients with treatment‐induced thrombocytopenia by luteinizing hormone‐releasing hormone agonist and depo‐medroxyprogesterone acetate via openalex
Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus via openalex
doi:10.1056/nejmra071297 via openalex
doi:10.1016/j.fertnstert.2009.06.033 via openalex
doi:10.1016/j.autrev.2005.10.001 via openalex
doi:10.1002/14651858.cd002265.pub3 via openalex
doi:10.1002/1529-0131(199909)42:9<1785::aid-anr1>3.0.co;2-# via openalex
doi:10.1016/b978-1-4160-4007-1.50153-x via openalex
doi:10.1089/jwh.2008.0857 via openalex
doi:10.1002/art.22204 via openalex
doi:10.1016/b978-1-4160-0016-7.50327-1 via openalex
doi:10.1016/j.rdc.2009.12.010 via openalex
doi:10.1016/j.fertnstert.2010.11.017 via openalex
W1488327342 via openalex
doi:10.1002/art.1780251101 via openalex
doi:10.1007/s10549-010-0996-7 via openalex
doi:10.1097/grf.0b013e3181f96cb1 via openalex
W2405735728 via openalex
W2411638432 via openalex
W2416876252 via openalex
W4241966887 via openalex
doi:10.1136/ard.2006.054593 via openalex
W6629349034 via openalex
W6697637764 via openalex
W6713434867 via openalex
W6715044815 via openalex
doi:10.1002/14651858.cd002265.pub2 via openalex
doi:10.1136/adc.2007.131334 via openalex
doi:10.1136/bmj.39358.519491.ad via openalex
doi:10.1002/14651858.cd010628.pub2 via openalex
doi:10.1097/00001703-200310000-00003 via openalex
doi:10.1002/art.1780400928 via openalex
doi:10.1093/humupd/dmn041 via openalex
doi:10.1038/sj.ki.5001630 via openalex
doi:10.1002/art.22449 via openalex
doi:10.1056/nejm198806023182203 via openalex
doi:10.3109/9780203214237-95 via openalex
doi:10.1111/j.1440-1797.2009.01101.x via openalex
doi:10.1200/jco.2010.28.15_suppl.528 via openalex
doi:10.1093/ndt/16.10.2018 via openalex
doi:10.1378/chest.130.1.182 via openalex
doi:10.1093/humupd/dmn022 via openalex
doi:10.1007/s10549-009-0313-5 via openalex
doi:10.1016/j.mpmed.2009.10.006 via openalex
doi:10.1191/096120300678828596 via openalex
doi:10.1002/art.1780401213 via openalex
doi:10.1016/j.fertnstert.2007.12.044 via openalex

Cited by (4)

Source provenance

openalex: last seen: 2026-05-14T06:07:48.142452+00:00

License: CC0 · commercial use OK

[1] Prevention of severe menorrhagia in oncology patients with treatment‐induced thrombocytopenia by luteinizing hormone‐releasing hormone agonist and depo‐medroxyprogesterone acetate 2006

[2] Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus 2005